Kornimate/medical-research-clean huggingface dataset:
surpoint algorithm for improved guidance of ablation for ventricular tachycardia

Conditions: Ventricular Tachycardia

Summary: vistag surpoint is a proprietary module that generates a numerical tag index which can be used as multiparametric lesion quality marker to guide ablation in the clinical setting for ablation of atrial arrhythmias. surpoint tag index has studied to guide ablation of ventricular arrhythmias, such as premature ventricular complexes, but its effectiveness and safety for ablation of ventricular tachycardia in patient with ischemic and non-ischemic cardiomyopathies is not well established. in this single center prospective observation registry, a ventricular ablation strategy utilizing radiofrequency delivery duration cut off determined by a maximum surpoint index value of 550 will be compared to conventional operator determined duration of radiofrequency delivery based on combination of time (i.e. 30, 60, 90, and 120 seconds), magnitude of impedance drop, attenuation of abnormal electrograms, and achieving non-capture with high-output pacing after ablation. the surpoint tag index ablation group will be matched with a control group of patients undergoing vt ablation using the conventional time-based radiofrequency strategy and the patients in this group will be selected using propensity matching based on relevant baseline patient and clinical characteristic variables. primary outcomes of interest: recurrence of sustained ventricular tachycardia or internal cardiac defibrillator therapy. secondary outcomes of interest: hospitalization for ventricular tachycardia, repeat ablation procedures, all-cause mortality, acute procedural complications, rate of steam pops during ablation procedures follow up: up to 24 months after ablation procedure. follow up will be obtained by office visits and device interrogation reports.


Eligibility criteria:
inclusion criteria: * structural heart disease: ischemic or non-ischemic cardiomyopathy * sustained monomorphic ventricular tachycardia documented by ecg or cied interrogation exclusion criteria: * if clinical ventricular arrhythmia is predominantly pvcs, polymorphic ventricular tachycardia, or ventricular fibrillation * myocardial infarction or cardiac surgery within 6 months * severe mitral regurgitation * stroke or tia within 6 months * prior ventricular tachycardia ablation
effect of oral isotretinoin on muscle strength in patients with acne vulgaris: a prospective controlled study

Conditions: Muscle Strength

Summary: background: musculoskeletal side effects related to isotretinoin are frequently reported. this study aimed to investigate the effect of oral isotretinoin treatment on muscle strength. our second aim was to evaluate whether there was a correlation between the serum creatine phosphokinase (cpk) level, a specific marker of muscle breakdown, and muscle strength. methods: this study included 30 patients who presented to our hospital and were started on oral isotretinoin treatment for acne vulgaris and 30 patients in the control group who were given local treatment. age, gender, height and weight of the patients were recorded, and the body mass index (bmi) was calculated. the hamstring and quadriceps muscle strengths of the non-dominant side were evaluated in all patients using an isokinetic dynamometer, and the peak torque (pt) values were recorded. in the isotretinoin group, isokinetic measurements were performed again in those that completed six-month drug treatment and compared with the initial pt values.

background: musculoskeletal side effects related to isotretinoin are frequently reported. this study aimed to investigate the effect of oral isotretinoin treatment on muscle strength. our second aim was to evaluate whether there was a correlation between the serum creatine phosphokinase (cpk) level, a specific marker of muscle breakdown, and muscle strength. methods: this study included 30 patients who presented to our hospital and were started on oral isotretinoin treatment for acne vulgaris and 30 patients in the control group who were given local treatment. age, gender, height and weight of the patients were recorded, and the body mass index (bmi) was calculated. the hamstring and quadriceps muscle strengths of the non-dominant side were evaluated in all patients using an isokinetic dynamometer, and the peak torque (pt) values were recorded. in the isotretinoin group, isokinetic measurements were performed again in those that completed six-month drug treatment and compared with the initial pt values.

Eligibility criteria:
inclusion criteria: * being aged 18-45 years * receiving isotretinoin treatment for the isotretinoin group * not having used isotretinoin within the last year for the control group exclusion criteria: * chronic kidney or liver disease, * uncontrolled hypertension, heart failure, * malignancy, * thyroid and bone diseases (e.g., hyperparathyroidism and osteomalacia), * use of drugs that may affect skeletal metabolism (e.g., corticosteroids, heparin, and anticonvulsants), * a history of trauma and/or surgery in the lower extremities. * patients who discontinued or terminated their isotretinoin treatment were not included in the study.

Keywords: isotretinoin muscle strength isokinetic creatinine phosphokinase
a randomized controlled trial of acupuncture for insulin resistance in patients with polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome (PCOS)

Summary: to determine the efficacy and safety of 2 different treatment modalities: 1) acupuncture plus lifestyle management (treatment group), 2) placebo plus lifestyle management (control group) in the treatment of insulin resistance in pcos patients.

a prospective, randomized controlled trial design was used to select women with polycystic ovary syndrome as the research subjects. 144 subjects who met the inclusion and exclusion criteria were randomly divided into an acupuncture plus lifestyle intervention group (treatment group) and a placebo plus lifestyle intervention group (control group). the differences in glucose metabolism and reproductive endocrinology were compared between the two groups. 1. to verify the efficacy and safety of acupuncture intervention on insulin resistance in pcos; 2. to explore the effects of acupuncture on androgen and lipid levels, ovarian function, reproductive dysfunction, mood and quality of life in women with pcos.

Eligibility criteria:
inclusion criteria: * for the pcos group, pcos diagnosis according to rotterdam criteria 2003 with at least two of the following three symptoms: (1) infrequent ovulation or anovulation; (2) hyperandrogenism or clinical manifestations of high blood androgen; (3) ultrasound findings of polycystic ovaries in 1 or 2 ovaries, or ≥12 follicles measuring 2 to 9 mm in diameter, and/or ovarian volume ≥10 ml exclusion criteria: 1. exclusion of other endocrine disorders such as androgen secreting tumors, suspected cushing's syndrome and non-classic congenital adrenal hyperplasia (17-hydroxyprogesterone \< 3nmol/l) thyroid dysfunction and hyperprolactinemia. 2. type i diabetes or not well controlled type ii diabetes 3. stage 2 hypertension (resting blood pressure ≥160/100mmhg) 4. psychiatric diagnoses or using psychiatric medications including antidepressants 5. pharmacological treatment (cortizone, antidepressant, other antidiabetic treatment such as insulin and acarbose, hormonal contraceptives, hormonal ovulation induction or other drugs judged by discretion of investigator) within 12 weeks. depo provera or similar within 6 months.

Keywords: insulin resistance
acupoint massage combined with ear point pressing beans

Conditions: Asthma

Summary: objective: to explore the application effect of acupoint massage combined with ear point pressing beans in the remission stage of asthma. methods: 120 children with asthma in remission who were treated in pediatric outpatient department from january 2016 to october 2022 were randomly divided into experimental group and control group, with 60 cases in each group.the patients in both groups were treated with salmeterol and fluticasone inhalation powder once a day, twice a day. the patients in the control group were treated with acupoint massage on this basis. acupoint massage once a day from monday to friday, lasting for 30 minutes each time.the patients in the experimental group were treated with ear point pressing beans on the basis of the control group. the ear point pressing beans is performed once a day from monday to friday. changes in pulmonary function and asthma control were observed before and after treatment in the two groups were observed, and forced expiratory volume 1 second (fev1),forced expiratory vital capacity (fvc), fev1/fvc, asthma control test scale (act) score were compared.


Eligibility criteria:
inclusion criteria: * the patient met the diagnostic criteria of asthma remission in the guidelines for prevention and treatment of bronchial asthma； * 1\~18 years old, course of disease \> 1 year; * patients with complete clinical data and able to cooperate with treatment. exclusion criteria: * patients with other cardiopulmonary system diseases or myasthenia gravis; * eczema, ulcer or other symptoms in the auricle or skin; * illiteracy, cognitive, language or communication disorders; * the patient has taken medication for asthma treatment within 3 months.
first-in-human study of single and multiple ascending doses of pf-06751979

Conditions: Healthy Subjects

Summary: the purpose of this study is to evaluate the safety, tolerability, pk and pd of pf-06751979 following oral doses in healthy adult and healthy elderly subjects.


Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects of non-childbearing potential between the ages of 18 and 55 years or between the ages of 60 and 85 years, inclusive. * body mass index (bmi) of 17.5 to 32 kg/m2; and a total body weight \>50 kg (110 lbs) at screening. * evidence of a personally signed and dated informed consent document indicating that the subject or a legally acceptable representative has been informed of all pertinent aspects of the study. exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). * male subjects with partners currently pregnant; male subjects able to father children who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product. * unwilling or unable to comply with the lifestyle guidelines described in this protocol. * subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are pfizer employees directly involved in the conduct of the study. * any severe acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.

Keywords: alzheimer's disease
interventions for postoperative delirium: biomarker-2 (ipod-b2)

Conditions: Delirium

Summary: the ipod-b2 study aims to understand the pathogenesis of postoperative delirium in patients undergoing major surgery. the investigators will identify then correlate soluble biomarkers in blood and cerebral spinal fluid with changes in high density-electroencephalogram.


Eligibility criteria:
inclusion criteria: 1. adult (\>21 years old) 2. patients scheduled for an elective open thoracoabdominal aortic aneurysm or tevar (thoracic endovascular aortic/aneurysm repair) 3. requiring spinal drain for surgery that is predicted to stay in two or more days 4. willing and able to provide informed consent exclusion criteria: 1. contraindication for spinal drain 2. documented history of dementia 3. unable to communicate with the research staff due to language barriers 4. individuals who the pi determines are not appropriate for the study such as a history of appointment cancellations. 5. pregnant or nursing 6. prisoners
the effects of a standardized management plan on children with critical asthma

Conditions: Children; Asthma

Summary: a standardized clinical assessment management plan (scamp) has been developed and implemented at boston children hospital to decrease variations in clinical practice in critical asthma therapies for children. the primary aim is to determine whether a critical asthma scamp can improve clinical outcome.

a standardized clinical assessment management plan (scamp) has been developed and implemented at boston children hospital to decrease variations in clinical practice in critical asthma therapies for children. however the effects of the critical asthma scamp on the clinical outcomes in children with critical asthma are unknown. this study will assess the effectiveness of the scamp by comparing retrospective data from medical records in children with critical asthma to prospective clinical ppsq scamp outcome data obtained during the qa process of the scamp. the primary aim is to determine whether a critical asthma scamp can improve clinical outcome. there are three specific pathways in the critical asthma scamp. the primary outcome measure is the length of intensive care length of stay (defined as time to every 2 hr intermittent albuterol nebulization) for all three pathways. the secondary aim is to validate a clinical asthma score to direct critical asthma therapies. to achieve this goal we will determine the relationships of the driver(s) of the scamp which includes boston children hospital (bch) asthma severity score \[hass\] and non-invasive measures of pco2 to standard measures of severity of asthma (blood gases and peak flow measurements).

Eligibility criteria:
inclusion criteria: * hospitalized patients 2 years and older requiring critical asthma therapies including continuous albuterol nebulization

Keywords: critical asthma children
alpha-lipoic acid in patients at risk for paclitaxel induced neuropathy

Conditions: Peripheral Neuropathy

Summary: this study is being done because peripheral neuropathy, a condition that interrupts sensation in your limbs, is a common side effect of paclitaxel. there is some evidence that alpha lipoic acid (ala), an antioxidant compound, protects neurons after exposure to paclitaxel. the purpose of this study is to assess the safety and tolerability of ala and to find the best dose of ala in patients that receive chemotherapy.


Eligibility criteria:
inclusion criteria 1. diagnosis of breast cancer. 2. breast cancer must meet the following criteria: * early stage breast cancer (stages i, iia) must be estrogen receptor (er) positive and low tumor grade (histopathologic grade 1 or 2) * locally advanced breast cancer (labc) (stages iib, iiia, iib as defined by the union for international cancer control and american joint committee on cancer) must be er positive, her2 positive or her2 negative, and satisfy the following requirements: high endocrine responsiveness (defined as greater than 50% of tumor cells staining for hormone receptors), grade 1 or 2 histological grade, less than 4 nodes positive, absence of extensive peritumoral vascular invasion, and pathological tumor size less than 5 cm. * inflammatory breast cancer (ibc) (stage iiic) * metastatic breast cancer (stage iv) 3. must be receiving single agent paclitaxel in their prescribed chemotherapy regimen. 4. age \> 18 years. there is no upper age limit for participation in this study. 5. required lab values: ast, alt, creatinine 6. women of childbearing potential and sexually active males must agree to use contraception while on study. 7. ecog performance status 0,1,2 8. all patients must have given signed, informed consent. exclusion criteria 1. breast cancer meeting the following criteria: * breast cancer stage 0 * early stage breast cancer (stages i, iia) that is er negative or higher tumor grade (histopathologic grade greater than 2) * stages i, ii, and iiia triple negative breast cancer (negative for estrogen receptors, progesterone receptors, and her2) * labc (stages iib, iiia, iib) if they have low endocrine responsiveness (defined as less than 50% of tumor cells staining for hormone receptors), grade 3 histological grade, 4 or more nodes positive, presence of extensive peritumoral vascular invasion, or pathological tumor size greater than 5 cm * labc (stages iib, iiia, iib) that are er negative 2. evidence of pre-existing peripheral neuropathy as determined by baseline michigan neuropathy screening instrument score \> 2. 3. previous chemotherapy treatment of any kind. 4. ast and alt \>2 times upper limit of normal; creatinine \> 2.0 mg/dl. 5. current use of medications or substances known to be associated with peripheral neuropathy. 6. use of ala or other anti-oxidant supplements during the prior three months. 7. diabetes mellitus or use of medications known to lower blood sugar. 8. participation in any other experimental trial.

Keywords: chemotherapy peripheral neuropathy paclitaxel breast cancer
a safety and efficacy study of pvx108 in children and adolescents with peanut allergy

Conditions: Peanut Allergy; Peanut Hypersensitivity; Peanut-Induced Anaphylaxis; Immune System Diseases

Summary: the overall aims of this study are to demonstrate that treatment with pvx108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with peanut allergy.


Eligibility criteria:
key inclusion criteria: * physician-diagnosed immunoglobulin e (ige) mediated peanut allergy; * peanut specific serum ige measured by immunocap® ≥ 0.7 kilounit allergy specific antibody per litre (kua/l) at screening; * positive skin prick test to peanut with mean wheal diameter ≥5 mm greater than negative control at screening; * positive peanut double blind placebo-controlled food challenge (dbpcfc) with a reactive dose ≤300 mg peanut protein (≤443 mg cumulative reactive dose \[crd\]); * able to perform spirometry or peak expiratory flow. children who are 4 years of age at screening stage 1 visit and unable to perform peak expiratory may be enrolled providing they had no clinical features of moderate or severe persistent asthma within 1 year prior to the screening visit; * forced expiratory volume in 1 second (fev1) ≥80% predicted in adolescents and children with asthma capable of performing spirometry, or peak expiratory flow ≥80% predicted in participants with asthma unable to perform spirometry (at investigator's discretion). key exclusion criteria: * history of or current clinically significant medical conditions or laboratory abnormalities which in the opinion of the investigator would jeopardise the safety of the participant or the validity of the study results; * severe or unstable asthma as assessed by the global initiative for asthma (gina) assessment of asthma control or current treatment for asthma at gina ≥step 4 level; * participants with skin disorders that would hinder skin prick testing and/or its interpretation or study drug administration (eg, severe generalised poorly controllable atopic dermatitis); * any medical condition in which epinephrine (adrenaline) is contraindicated; * prior therapy aimed at desensitising peanut allergy, either in a formal study or in clinical practice; * severe or life-threatening reaction during the screening food challenge, at investigator discretion.

Keywords: peanut allergy arachis child adolescent immunotherapy
trimethoprim-sulfamethoxazole vs levofloxacin as targeted therapy for stenotrophomonas maltophilia infections: a retrospective cohort study

Conditions: Stenotrophomonas Infection

Summary: this study seeks to compare mortality outcomes of levofloxacin and trimethoprim-sulfamethoxazole treated patients who have stenotrophomonas maltophilia blood stream or lower respiratory tract infections by retrospectively analyzing a propensity-matched cohort from a large dataset of electronic health record data.


Eligibility criteria:
inclusion criteria: * 18 years of age and older * stenotrophomonas maltophilia culture positive from blood or the following specified respiratory tract sites: sputum, tracheal aspirate, bronchoalveolar lavage and protected bronchial brush washings * received either levofloxacin or tmp/smx targeted therapy * those patients that received empiric therapy with a consistent medication (for example, levofloxacin empirically in the levofloxacin targeted therapy cohort) were included exclusion criteria: * received antimicrobial other than tmp/smx and levofloxacin, with known activity against stenotrophomonas maltophilia (the list of antimicrobials that fit this exclusion criteria is: erythromycin, moxifloxacin, ciprofloxacin, minocycline, tigecycline, doxycycline, eravacycline, ceftazidime, cefepime, ticarcillin-clavulanate, cefiderocol, colistin, and chloramphenicol) * received inconsistent empiric therapy (for example, levofloxacin empirically in the tmp/smx targeted therapy cohort) will be excluded from analysis * cystic fibrosis code present * organism resistant to therapy received

Keywords: stenotrophomonas maltophilia, stenotrophomonas, levofloxacin, tmp/smx, trimethoprim-sulfamethoxazole
gasc1 inhibitor caffeic acid for squamous esophageal cell cancer (escc)

Conditions: Esophagus Cancer, Stage III

Summary: caffeic acid can target inhibit gasc1 (gene amplified in squamous cell carcinoma 1, also known as kdm4c and jmjd2c) expression and gasc1 is confirmed to be a new oncogene in several cancers including esophageal cancer. this study aims to investigate the efficiency and safety of coffeic acid in chinese advanced esophageal squamous cell cancer (escc).

background: more than half of global esophageal cancer cases came from china.80 percentage patients were diagnosed with advanced disease and suffered from the poor outcome.with the development of target therapy among cancers,the overall survival and life quality of patients has been continuous improved recently.however,there had little reports focusing on target therapy in esophageal cancer . caffeic acid as an ordinary drug is used for thrombocytopenia when patient received chemotherapy. newly studies shown caffeic acid can target inhibit gasc1 expression, and gasc1 is confirmed to be a new oncogene in esophageal cancer. aim: to investigate the efficiency and safety of caffeic acid in chinese advanced esophageal squamous cell cancer. methods: 80 advanced escc patients who failed to the chemotherapy or chemoradiotherapy (1 or 2 line) will be randomized to two arms: arm a and arm b. in arm a, 40 patients will receive coffeic acid treatment: 100-200mg, tid, po, 2 weeks treated then 1 week black interval(weight \>50kg, 200mg per time, weight \< or =50kg, 100mg per time; in arm b, 40 patients will receive the placebo tablets. 1 years follow-up for all patients in this trial. patients in both arms can receive any other ways of anti cancer therapy in the same time. primary endpoints: os; second endpoints: pfs

Eligibility criteria:
inclusion criteria: 1. chinese 2. esophageal squamous cell cancer 3. stage iv or recurrence disease 4. chemotherapy, or radiotherapy, or palliative care is going on exclusion criteria: 1. ps (performance status): ≥ 3 2. severe hepatic and renal dysfunction 3. hypercoagulability 4. thrombocytosis

Keywords: esophageal cancer caffeic acid